Photo from DC_Studio on Envato
One of the drivers is the introduction of drugs that target unmet needs.
GlobalData said the heart failure (HF) segment across seven major markets is expected to reach $3.37 billion by 2032, growing at a CAGR of 9.6%.
Key drivers of expansion include the development of therapeutic strategies and the launch of drugs targeting unmet needs.
At the same time, pharmaceutical companies are working to improve treatment safety, compliance, and develop new drug classes.
Kajal Jaddoo, senior pharmaceutical analyst at GlobalData, said new entrants to the heart failure market may be successful if they offer new treatments that address unmet clinical needs or improve patient compliance.
7MM = United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Join the Asian Healthcare Magazine Community
Now that you're here…
….There are many ways you can work with us to promote your company and connect with your customers. Our team can help you plan and create print and digital advertising campaigns on this website and in the print magazine.
We can also organize real-life or digital events for you and source thought-leader speakers and industry leaders (who may be your potential partners) to attend your events. We also run a number of awards programs that give you the opportunity to be recognized for your achievements during the year, and you can join as a participant or sponsor.
Let us help you drive business development through good partnerships!
